Something doesn’t add up in a handful of Republican-led states right now. At the very moment the party finally has a real answer to one of the most persistent frustrations in American life, the cost of prescription drugs, some lawmakers are advancing policies that could make that solution harder to access.
And they are doing it to themselves.
The rollout of TrumpRx was not another abstract policy promise. It was something tangible. Americans can walk into a pharmacy, present a discount card, and see the price drop immediately. In many cases, dramatically. At launch, the program delivered discounts ranging from roughly 33% to as high as 93% on brand-name medications, including widely used drugs for diabetes, weight loss, fertility, and chronic respiratory conditions.
For years, both parties talked about lowering drug prices. President Donald Trump built a system that actually does it.
But here is the part that some state lawmakers seem to be missing. TrumpRx does not exist in a vacuum. It depends on a nationwide retail pharmacy network to function. It works because Americans can use it at familiar, accessible locations in their own communities.
That includes major chains like CVS Health, Walgreens, Kroger, Albertsons, and Costco. These companies are not peripheral to the system. They are the system. One of them alone operates roughly 9,000 pharmacy locations nationwide and has been identified as a key partner in making TrumpRx accessible to patients.
These pharmacies are part of the reason programs like TrumpRx can deliver the kind of discounts that have proven so meaningful to patients. Which is what makes the current push in states like Tennessee and Oklahoma so concerning.
Legislation such as Tennessee’s SB 2040 and Oklahoma’s HB 3538 targets Pharmacy Benefit Managers (PBMs), specifically the structure that allows them to operate alongside retail pharmacies. The bills would prohibit PBMs from owning or operating pharmacies, forcing vertically integrated companies to split apart or shut down parts of their business.
On paper, that may sound like a technical fix. In reality, it creates immediate and far-reaching consequences.
In Tennessee, this approach could lead to the closure of more than 130 pharmacy locations and dozens of in-store clinics that serve approximately 1.5 million patients each year. In Oklahoma, more than 60 pharmacy locations are at risk under similar proposals. Across multiple states considering this model, the cumulative effect could be thousands of lost pharmacy access points.
And these are not small operations. Chain pharmacies handle an outsized share of prescription volume. On average, they fill nearly three times as many prescriptions per location as independent pharmacies. That capacity matters. When those locations disappear, smaller providers are often not in a position to absorb the demand, particularly when reimbursement structures make it difficult to take on additional patients.
The result is fewer options, longer wait times, and in some cases, entire communities left without a reliable place to fill prescriptions.
This is where the potential damage to the President’s signature drug pricing effort becomes impossible to ignore.
TrumpRx is built on access. It lowers prices, but only if patients can actually use the discounts. It relies on a dense, functioning network of pharmacies to deliver those savings in the real world.
If lawmakers force the closure of the very pharmacies that accept TrumpRx, they are not improving the system. They are weakening it. A discount means very little if there is nowhere nearby to use it.
Supporters of these bills argue that targeting PBMs will reduce drug prices. But that claim assumes that removing or weakening one of the few actors in the system specifically tasked with applying downward pressure on drug prices by negotiating with manufacturers will somehow lead to lower costs. There is little evidence to support that, and real reason to believe the opposite could happen.
There is also a broader issue that should not be ignored. Republicans have long championed limited government and market-driven solutions. Forcing companies to restructure their business models through legislation is a significant intervention. It raises a fair question about whether the party is staying true to its own economic principles.
And then there is the political reality. With the 2026 midterm elections approaching, Republicans are preparing to make their case on cost-of-living issues, especially healthcare. TrumpRx is the clearest example they have of a policy that delivers immediate, measurable relief. It is easy to understand, easy to use, and already making a difference for patients across the country.
Why make it harder to access? Why risk turning a clear success into a self-inflicted problem?
The better path is not complicated. Strengthen the system that is already lowering prices. Protect the pharmacy network that makes those savings possible. Ensure that Americans can not only access discounts on paper but actually use them where it matters most.
Because in the end, this is not about regulatory theory. It is about whether someone can walk into a pharmacy, get the medication they need, and afford it. TrumpRx makes that possible. State policies that close pharmacies put it at risk.
Like what you’re reading? There’s a lot more where that came from.
PJ Media VIP members get deeper dives, exclusive columns, and commentary you won’t see on the public side. Best of all, you can get 60% off right now with the promo code FIGHT.
Sign up for PJ Media VIP and help us keep telling the stories that matter.
